AU2003294668A1 - Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas - Google Patents

Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Info

Publication number
AU2003294668A1
AU2003294668A1 AU2003294668A AU2003294668A AU2003294668A1 AU 2003294668 A1 AU2003294668 A1 AU 2003294668A1 AU 2003294668 A AU2003294668 A AU 2003294668A AU 2003294668 A AU2003294668 A AU 2003294668A AU 2003294668 A1 AU2003294668 A1 AU 2003294668A1
Authority
AU
Australia
Prior art keywords
liposarcomas
jnk
diagnosis
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003294668A
Other versions
AU2003294668A8 (en
Inventor
Alain Aurias
Frederic Chibon
Odette Mariani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Original Assignee
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie filed Critical Institut Curie
Publication of AU2003294668A1 publication Critical patent/AU2003294668A1/en
Publication of AU2003294668A8 publication Critical patent/AU2003294668A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
AU2003294668A 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas Abandoned AU2003294668A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292195.1 2002-09-06
EP02292195 2002-09-06
PCT/EP2003/009867 WO2004026407A1 (en) 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Publications (2)

Publication Number Publication Date
AU2003294668A1 true AU2003294668A1 (en) 2004-04-08
AU2003294668A8 AU2003294668A8 (en) 2004-04-08

Family

ID=31502838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294668A Abandoned AU2003294668A1 (en) 2002-09-06 2003-09-05 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas

Country Status (2)

Country Link
AU (1) AU2003294668A1 (en)
WO (1) WO2004026407A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005114199A1 (en) * 2004-05-13 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 5 (map3k5)
JP2012521760A (en) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
JP3839103B2 (en) * 1996-04-19 2006-11-01 財団法人癌研究会 Apoptosis-inducing protein and gene encoding the same
JP2002501743A (en) * 1998-01-30 2002-01-22 ジェネセンス テクノロジーズ インコーポレイテッド Oligonucleotide sequences complementary to thioredoxin gene or thioredoxin reductase gene and methods of using same to regulate cell growth
US6080546A (en) * 1999-07-23 2000-06-27 Isis Pharmaceuticals Inc. Antisense modulation of MEKK5 expression
WO2002026803A2 (en) * 2000-09-25 2002-04-04 Millenium Pharmaceuticals, Inc. 22108 and 47916, novel human thioredoxin family members and uses thereof
WO2001080849A1 (en) * 2000-04-26 2001-11-01 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Method of treating cancer
KR100399982B1 (en) * 2000-06-16 2003-11-13 학교법인고려중앙학원 Novel mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting with ASK1 and use thereof
JP2002069005A (en) * 2000-08-30 2002-03-08 Japan Science & Technology Corp Solid carcinoma-curing formulation
AU2002243429A1 (en) * 2000-10-24 2002-06-24 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression

Also Published As

Publication number Publication date
AU2003294668A8 (en) 2004-04-08
WO2004026407A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
EP1804794A4 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer s disease
HK1078779A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
AP2006003633A0 (en) Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
IL165257A0 (en) 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003203378A1 (en) Suture insrument for biological use
HK1067362A1 (en) Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
WO2004043379A3 (en) Chemical compounds
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002353147A1 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
WO2002056876A3 (en) Treatment for snoring
AU2003290939A1 (en) Replication of biological tiussue
SI1603570T1 (en) Aminoheteroaryl compounds as protein kinase inhibitors
AU2003214145A1 (en) Medical use of ras antagonists for the treatment of capillary malformation
AU2003294668A1 (en) Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
AU2003270683A1 (en) Compounds for the treatment of premature ejaculation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 19, PAGE(S) 5408 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME INSTITUT CURIE, APPLICATION NO. 2003294668, UNDER INID (71) CORRECT THE NAME TO READ INSTITUT CURIE; UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM